Vascular endothelial growth factor in the fluid of the anterior chamber of the eye in patients with diabetic retinopathy, cataract andneovascular glaucoma

Aim.
To study the role of vascular endothelial growth factor (VEGF-A) in the fluid of the anterior chamber of the eye (ACE) in the evolvement ofdiabetic retinopathy (DR) and the outcome of cataract surgery.
Materials and methods.
The study included 120 patients with diabetes mellitus (DM) operated for the removal of cataract. 16 patients received treatmentfor DR-related neovascular glaucoma (NG). The control group comprised 22 subjects without DM. VEGF-A and glucose levels were measuredin the ACE fluid prior to surgery.
Results.
Patients with DM were not significantly different in terms of VEGF-A, fasting glucose, and HbA_1c levels on the day of surgery excepting DMpatients without DR. VEGF-A and glucose levels in AEG increased in proportion to DR severity. VEGF-A concentration was minimal in the absenceof DR (22.75 pg/ml [10.78; 63.36]) and amounted to 336.6 pg/ml [232.3; 410.74] in patients with DM and DR (P<0.0001). In DM combined withNG the VEGF-A level increased to 1634.01 pg/ml [610.69; 2657.33] (17 times the level in control subjects). Visual acuity in the late postoperativeperiod gradually decreased to the preoperative values 12 months after surgery for severe DR. Thereafter, 7.6% of the patients developed NG. 40% ofthe patients were treated by retinal laser coagulation; postoperative complications were absent only in 52.4% of the cases.
Conclusion.
High VEGF-A level in the ACE fluid (above 137.4 pg/ml) greatly contributes to the development of NG after removal of cataract and increases9.62-12.3 times the risk of NG.

VEGF, vascular endothelial growth factor (VEGF-A), diabetic retinopathy, cataract, cataract surgery

1. World Health Organization. Sight test and glasses could dramatically improve the lives of 150 million people with poor vision // Press release, 11 October 2006. http://www.who.int/mediacentre/news/releases/ 2006/pr55/en/index.html.

2. Дедов И.И., Шестакова М.В., Миленькая Т.М. Сахарный диабет: ре- тинопатия, нефропатия. - М., 2001. - 161 с.

3. Dagher Z., Park Y.S., Asnaghi V. et al. Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy // Diabetes. - 2004. - Vol. 53. - P. 2404-2411.

4. Pournaras C.J., Rungger-Brдndle E., Riva C.E., Hardarson S.H., Stefansson E. Regulation of retinal blood flow in health and disease // Prog. Retin. Eye. Res. - 2008. -Vol. 27(3). - P. 284-330.

5. The diabetes control and complications trial research group. The affect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus // N. Engl. J. Med. - 1993. - Vol. 329. - P. 977-986.

6. Шестакова М.В., Северина А.С. Эндотелиальная дисфункция, си- стема ангиогенеза и система гемостаза при сахарном диабете. Руко- водство для врачей. - М., 2005. - 54 с.

7. Aiello L.P., Northrup J.M., Keyt B.A., Takagi H., Iwamoto M.A. Hypoxic regulation of vascular endothelial growth factor in retinal cells // Arch. Ophthalmol. - 1995. Vol. 113. - P. 1538-1544.

8. Simу R., Carrasco E., Garcнa-Ramнrez M., Hernбndez C. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy // Curr. Diabetes. Rev. - 2006. - Vol. 2(1). - P. 71-98.

9. Robert S. Kerbel. Tumor angiogenesis // N. Engl. J. Med. - 2008. - Vol. 358. - P. 2039-2049.

10. Gragoudas E.S., Adamis A.P., Cunningham E.T., Feinsod M., Guyer D.R. Pegaptamib for neovascular age-related macular degeneration // N. Engl. J. Med. - 2004. - Vol. 351. - P. 2805-2816.

11. Rosenfeld P.J., Brown D.M., Heier J.S., Boyer D.S., Kaiser P.K., Chung C.Y., Kim R.Y. Ranibizumab for neovascular age-related macular degeneration // N. Engl. J. Med. - 2006. - Vol. 355. - P. 1419-1431.

12. Смирнова О.М., Кузьмин А.Г., Липатов Д.В., Шестакова М.В. Перспективы лечения ДР: воздействие на фактор роста эндотелия (обзор литературы) // Сахарный диабет - 2009. - Т. 2 - С. 33- 38.